Can a blood vessel drug ease Raynaud's in scleroderma?
NCT ID NCT02260557
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether selexipag, a drug that opens blood vessels, can reduce the number of Raynaud's attacks in adults with systemic sclerosis. 74 participants took either selexipag or a placebo twice daily. The main goal was to see if the drug lowered weekly attack frequency.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selexipag
- What this could lead to
- If it works, this could point toward a new treatment to reduce the number of Raynaud's attacks in people with systemic sclerosis.
- What could go wrong
- This is an early Phase 2 trial with only 74 people, so results may not be conclusive. The drug may not reduce attacks more than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Investigator Site
Grenoble, 38043, France
-
Investigator Site
Lille, 59037, France
-
Investigator Site
Nantes, 44093, France
-
Investigator Site
Paris, 75679, France
-
Investigator Site
Strasbourg, 67200, France
-
Investigator Site
Bad Nauheim, 61231, Germany
-
Investigator Site
Berlin, 10117, Germany
-
Investigator Site
Cologne, 50937, Germany
-
Investigator Site
Erlangen, 91054, Germany
-
Investigator Site
Magdeburg, 39120, Germany
-
Investigator Site
Mainz, 55131, Germany
-
Investigator Site
Bath, BA11RL, United Kingdom
-
Investigator Site
Leeds, LS74SA, United Kingdom
-
Investigator Site
Liverpool, L97AL, United Kingdom
-
Investigator Site
London, NW32QG, United Kingdom
-
Investigator Site
Salford, M55AP, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.